PTEN and melanoma: To probe the latter possibility, we performed in vivo experiments in a mouse melanoma model, using the Yumm1.7 cell line, which harbors the activating BrafV600E mutation, is homozygous negative for Pten and Cdkn2, and is syngeneic with immunocompetent C57/B1/6 mice.29